Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2026, specifically reporting on share repurchase transactions executed between June 15 and June 19, 2026. The filing details a non-discretionary buyback program initiated on May 8, 2026, executed through Citigroup Global Markets Limited.
Key Financial Metrics and Share Data
The filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Total Shares Purchased (May 11 - June 19, 2026): 8,448,125 ordinary shares.
- Treasury Shares Held: 269,826,411 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,046,440,349 ordinary shares.
- Total Voting Rights: 4,046,440,349.
- Treasury Share Voting Percentage: 6.67%.
Operational metrics such as revenue, profit, cash flow, margins, debt, and liquidity are not provided in this filing text.
Material Changes and Transaction Details
The filing reports a series of daily purchases under an existing buyback program. The specific transaction details for the week of June 15-19, 2026, are as follows:
| Date | Shares Purchased | Lowest Price (GBp) | Highest Price (GBp) | VWAP (GBp) |
|---|---|---|---|---|
| 15 June 2026 | 215,325 | 1,955.50 | 1,988.50 | 1,971.11 |
| 16 June 2026 | 214,000 | 1,940.50 | 1,968.00 | 1,954.16 |
| 17 June 2026 | 209,874 | 1,936.00 | 1,973.50 | 1,954.80 |
| 18 June 2026 | 245,840 | 1,906.00 | 1,978.00 | 1,942.62 |
| 19 June 2026 | 216,850 | 1,918.00 | 1,942.50 | 1,934.67 |
These purchases resulted in a reduction of shares in issue and an increase in the treasury share count, impacting the denominator for shareholder notification thresholds under FCA Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding future earnings or operational strategy. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the 2025 Annual Report on Form 20-F and Q1 2026 Results. No unusual items or contingencies are disclosed in this specific text.
Investor Verification Checklist
- Verify the total cumulative spend on the buyback program since May 11, 2026, by calculating the weighted average price against the 8,448,125 shares purchased.
- Confirm the updated share count (4,046,440,349) against the company's latest capitalization table to ensure accurate voting right calculations.
- Review the referenced 2025 Form 20-F and Q1 2026 Results for the risk factors and operational context mentioned in the cautionary statement.
- Check the full breakdown of individual trades via the provided RNS link for granular execution analysis on the London Stock Exchange and CBOE Europe.